Overview - Digital SCHOTT Pharmaversity®

Offering training sessions from experts in primary packaging solutions, the Pharmaversity^® is an inspirational networking hub where pharmaceutical companies can gain exclusive insights and scientific knowledge on primary packaging from the world’s leading glass and polymer specialists.

The Pharmaversity^® is a unique teaching platform that enables experts in pharmaceutical packaging to share their knowledge and experience. As a place to exchange ideas and information, the Pharmaversity^® brings together people from across the industry to explore solutions to tomorrow’s challenges.

For pen cartridges and autoinjectors, stopper position and fill volume decide device performance — and standard tolerances force a costly two-stage “sensor filling” process. We show how a high-precision COC cartridge reaches the required stopper precision in a single filling stage on standard fill-finish lines, proven by Bausch+Ströbel data.

Session learnings:

Why one step is now possible: how a COC cartridge’s tightly controlled internal diameter lets a single volumetric fill meet the stopper-position and residual-air-bubble requirement — removing the two-stage “sensor filling” that conventional tolerances demand.
The evidence: measured Bausch+Ströbel capability data (Cpk 1.95–3.32; 1σ = 0.050–0.086 mm) proving ±0.5 mm stopper precision across the full fill range and two stopper suppliers.
The business impact: single-step filling on standard fill-finish lines raises output and lowers CAPEX, operating cost, complexity and footprint — without any new device tolerance.

As biologics grow larger and more viscous, large-volume subcutaneous delivery is pushing conventional injection systems beyond their limits. Selecting the ideal primary packaging and delivery platform early in development is critical to ensuring successful and patient-centric drug delivery.

This session introduces an integrated solution: SCHOTT Pharma's large-volume containment solutions, including 5.5 mL prefillable glass syringes and the 10 mL cartriQ^® RTU glass cartridge systems, through ten23's non-GMP/GMP filling and device assembly, YpsoMate^® 5.5 autoinjector, and YpsoDose^® wearable device. Such close integration de-risks and accelerates scale-up for combination products, and streamlines the path from early development to commercial launch.

Session learnings:

Primary packaging as the foundation: How large-volume prefillable glass syringes (e.g., 5.5 mL) and glass cartridge systems (e.g., 10 mL) enable different subcutaneous delivery strategies and support evolving biologic drug requirements.
From development to commercial-scale filling and assembly: How ten23's non-GMP-to-GMP filling pathway, combined with in-house device assembly, de-risks and accelerates time to clinic and to market.
Device performance meets patient experience: How large-volume prefilled syringes paired with autoinjectors and large-volume glass cartridges with wearable devices translate complex dosing regimens into practical, patient-friendly delivery experiences.

As advanced biologics and combination products continue to drive demand for reliable cartridge-based delivery systems, a comprehensive understanding of both material compatibility and packaging performance is critical. This webinar combines insights from a 3 mL cartridge Extractables & Leachables (E&L) study with key considerations from USP <382> to provide a holistic approach to container closure system qualification.

Attendees will learn how chemical characterization and functional performance testing complement each other to support risk assessment, regulatory compliance, and robust packaging selection. Using practical examples from a 3 mL cartridge platform, the session will highlight strategies for ensuring product quality, patient safety, and device compatibility in autoinjector and other advanced drug delivery applications.

Session learnings:

Role of E&L studies in cartridge qualification
Relevance of USP <382> for elastomeric closure systems
Integration of chemical and functional performance assessments
Considerations for cartridge-based combination products
Supporting a science-based, risk-driven qualification strategy